Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up

作者
A. Goldhirsch,Martine J Piccart,Marion Jennifer Procter,Evandro de Azambuja,HA Weber,Michael Untch,Ian Smith,Luca Gianni,C Jackisch,David Cameron,R. Bell,Mitch Dowsett,Richard D. Gelber,Bryan Leyland-Jones,Jose M Baselga,the HERA Study Team
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:72 (24_Supplement): S5-2 被引量:46
标识
DOI:10.1158/0008-5472.sabcs12-s5-2
摘要

Abstract Background: One year (yr) of trastuzumab (T) significantly improves disease-free (DFS) and overall survival (OS) in patients with HER2-positive early breast cancer (EBC) and is considered the standard of care. HERA is the only randomized trial investigating whether longer duration of T can further improve efficacy outcome. Materials and Methods: HERA (BIG 01–01) is an international, multicenter, phase III randomized trial involving 5102 women with HER2-positive EBC. Pts were randomized, after completion of primary therapy [surgery, chemotherapy and radiotherapy as indicated], to T every 3 weeks for 1 yr, 2 years (yrs), or observation. This landmark efficacy analysis compares the outcome of pts randomized to either 2 yrs or 1 yr of T who were disease-free at 1 yr after randomization (N = 1553 for 2 yrs, and N=1552 for 1 yr). The primary endpoint is DFS and secondary endpoints are OS and time to distant recurrence (TTDR). Updated efficacy analyses of the T arms vs. observation at 8-yrs of median follow-up (FU) are also presented. Results: On 12 April 2012 HERA reached the target number of 725 DFS events needed for 80% power to detect a true hazard ratio (HR) of 0.80 for the comparison of 2 yrs vs. 1 yr of T. The unadjusted HR for an event in the 2-yr vs. 1-yr T arms was 0.99 (95% CI 0.85–1.14; p = 0.86). OS in the two arms was comparable [HR=1.05 (95% CI 0.86–1.28; p = 0.63)]. TTDR results were similar. The primary cardiac endpoint* was comparable (1.0% vs. 0.8% for 2-yr and 1-yr arms, respectively), but the secondary cardiac endpoint** was higher in the 2-yr arm (7.2% vs. 4.1%). Importantly, the durable benefit in DFS and OS for both 1 yr and 2 yrs of T compared with observation remains stable at 8 yrs of median FU. Subgroup analyses including by hormone receptor status will be available for the meeting. Conclusions: These results confirm that 1 yr of adjuvant T remains the standard of care for HER2-positive EBC pts. It is also reassuring that the significant improvement in DFS and OS persists over time and that the incidence of cardiac endpoints remains low at a median FU of 8 yrs. * NYHA class III or IV, confirmed by a cardiologist, and LVEF < 50% and ≥ 10% below baseline, OR cardiac death. ** LVEF < 50% and ≥ 10% below baseline confirmed by repeat assessment, excluding patients with a primary cardiac endpoint. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr S5-2.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wangbw发布了新的文献求助10
刚刚
缺口口发布了新的文献求助80
1秒前
leyi发布了新的文献求助10
1秒前
1秒前
six发布了新的文献求助10
1秒前
2秒前
9dingyushu完成签到,获得积分10
2秒前
2秒前
深情安青的应助被LuoYR@SZU采纳,获得10
3秒前
威武渊思发布了新的文献求助10
5秒前
秋风的应助被www采纳,获得10
6秒前
Ava的应助被无船付采纳,获得10
6秒前
红红发布了新的文献求助10
6秒前
6秒前
mhx1234567890发布了新的文献求助10
7秒前
科烟生发布了新的文献求助10
7秒前
三达不溜完成签到,获得积分20
7秒前
苏世发布了新的文献求助20
8秒前
斯文败类的应助被英勇的铸海采纳,获得10
8秒前
华仔的应助被liu采纳,获得10
8秒前
9秒前
liuze发布了新的文献求助10
9秒前
哈弟发布了新的文献求助10
9秒前
搜集达人的应助被害羞的宛亦采纳,获得10
10秒前
hin完成签到,获得积分20
10秒前
10秒前
三达不溜发布了新的文献求助10
10秒前
11秒前
赘婿的应助被maT采纳,获得10
11秒前
慕青的应助被紧张的文博采纳,获得10
11秒前
HANA发布了新的文献求助10
12秒前
rrr关闭了rrr的文献求助
12秒前
小蘑菇的应助被直率万声采纳,获得10
13秒前
烦烦烦发布了新的文献求助10
13秒前
LuoYR@SZU发布了新的文献求助10
14秒前
14秒前
隐形曼青的应助被晚风采纳,获得10
14秒前
wangbw发布了新的文献求助10
15秒前
聪明甜桃发布了新的文献求助10
16秒前
默默发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593